Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study

BACKGROUND AND AIMS: In recent years, biological agents, such as anti-TNF-α blockers, have been introduced and have shown efficacy in pediatric patients with inflammatory bowel disease (IBD). Here, the prescription mode differentiated into a first/second line application, and efficacy and side effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Claßen, Merle, de Laffolie, Jan, Claßen, Martin, Schnell, Alexander, Sohrabi, Keywan, Hoerning, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595023/
https://www.ncbi.nlm.nih.gov/pubmed/36304532
http://dx.doi.org/10.3389/fped.2022.903677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595023/
https://www.ncbi.nlm.nih.gov/pubmed/36304532
http://dx.doi.org/10.3389/fped.2022.903677

Ejemplares similares